Zepbound and Wegovy are the two branded weight-management injections most cash payers end up choosing between, and they are not the same drug. Zepbound is tirzepatide from Eli Lilly. Wegovy is semaglutide from Novo Nordisk. Different molecules, different manufacturers, different discount programs, and therefore different prices.
Both companies now sell direct to cash payers at roughly a quarter to a third of list price, which means the useful comparison is not “what does the pharmacy charge” but “what does each manufacturer charge, at your dose, for a year.” This guide prices both ladders as published on September 4, 2026, converts them to a 12-month cash cost, and explains the coverage differences that decide what you actually face at the counter. For a single-brand deep dive, see our Zepbound cost guide and our Wegovy cost guide.
What Does Zepbound vs. Wegovy Cost Without Insurance?
Every figure below was read directly from the manufacturers’ own pages on September 4, 2026.
| Route | Low | Average | High |
|---|---|---|---|
| Zepbound self-pay, LillyDirect (KwikPen or 4 vials) | $299/mo (2.5 mg) | $449/mo (7.5 to 15 mg) | $699/mo (10 to 15 mg, regular price) |
| Wegovy self-pay pen, NovoCare | $199/mo (first 2 fills, 0.25 and 0.5 mg) | $349/mo (0.25 to 2.4 mg) | $399/mo (Wegovy HD 7.2 mg) |
| Wegovy self-pay tablets, NovoCare | $149/mo (1.5 mg) | $199/mo (4 mg) | $299/mo (9 and 25 mg) |
| Savings card, commercial plan that covers the drug | $25/mo | $25/mo | Savings capped at $100/mo either way |
| Medicare GLP-1 Bridge, if eligible | $50/mo | $50/mo | Wegovy any form; Zepbound KwikPen only |
| What the pharmacy pays (CMS NADAC, Aug 19 2026) | $482/mo (Zepbound KwikPen 2.5 mg) | $678/mo (Zepbound KwikPen 12.5 mg) | $1,307/mo (Wegovy pens) |
| Manufacturer list price (WAC) | $499 per Zepbound fill | $1,086.37 per Zepbound fill | $1,349.02 per Wegovy package |
Zepbound’s self-pay ladder comes from LillyDirect: $299 for 2.5 mg, $399 for 5 mg, and $449 for 7.5 mg, 10 mg, 12.5 mg and 15 mg. Lilly’s terms are specific about what that $449 depends on. It reflects the Zepbound Journey Program, and the regular price applies if you do not refill within 45 days: $499 for 7.5 mg and $699 for 10 mg, 12.5 mg and 15 mg. Lilly’s own pricing page states the unconditioned direct-to-patient ladder as $299, $399, $499, $699, $699 and $699.
One detail that trips up comparisons: those prices are for the Zepbound KwikPen or the four-vial pack. Lilly’s savings page states plainly that the $299 per month figure is for the KwikPen or vial, not the Zepbound single-dose Pen. If you are pricing formats, our Zepbound vials and Zepbound KwikPen guides go dose by dose.
Wegovy’s ladder comes from NovoCare Pharmacy. Standard pens are $349 a month at 0.25 mg, 0.5 mg, 1 mg, 1.7 mg and 2.4 mg, with one month defined as one box of four pens. Wegovy HD 7.2 mg is $399. Patients new to the Wegovy Savings Offer or to NovoCare Pharmacy pay $199 for each month of the 0.25 mg and 0.5 mg starter doses, for two monthly fills, through December 31, 2026. Tablets run $149, $199 and $299 by dose, with one month defined as a bottle of 30.
The 12-month cash cost, side by side
Monthly prices are easy to compare wrongly, because the two ladders peak at different points. Here is what a full year at a maintenance dose actually costs a cash payer.
| 12 months at a maintenance dose | Monthly | 12-month cash cost |
|---|---|---|
| Zepbound 10 mg, refilled within 45 days | $449 | $5,388 |
| Zepbound 10 mg, regular price | $699 | $8,388 |
| Wegovy pen 2.4 mg | $349 | $4,188 |
| Wegovy HD pen 7.2 mg | $399 | $4,788 |
| Wegovy tablets 25 mg | $299 | $3,588 |
At a maintenance dose, Wegovy pens cost $1,200 less per year than Zepbound, and Wegovy tablets cost $1,800 less. If you miss the Zepbound refill window, the gap widens to $4,200 a year. Those are arithmetic on published prices, not projections.
What Drives the Price
Which manufacturer program you are inside. This is worth more than anything else on the page. CMS’s National Average Drug Acquisition Cost survey, effective August 19, 2026, puts what pharmacies themselves pay at roughly $1,303 to $1,307 a month for Wegovy pens and about $1,051 a month for Zepbound single-dose pens. Both self-pay prices sit well below that, which tells you the manufacturer channel is not a discount off retail, it is a separate market.
Your dose, but only for Zepbound. Wegovy charges $349 whether you are at 0.25 mg or 2.4 mg. Zepbound steps from $299 to $399 to $449. So Zepbound is cheaper at the start and more expensive at maintenance.
The 45-day refill clock. On Zepbound’s four highest doses, a late refill moves you from $449 to $499 or $699. Wegovy has no equivalent penalty. This single calendar rule is worth up to $250 a month.
Device format. NADAC prices the Zepbound KwikPen at about $482 to $678 for a 28-day month and the Zepbound single-dose pen at about $1,051, for the identical molecule and dose. Lilly’s self-pay prices apply to the KwikPen and vial, not the single-dose Pen, so the format on your prescription matters.
What each drug is approved to treat. Zepbound is Lilly’s weight-management brand. Wegovy carries more approved uses, which is why insurers treat it differently: FDA approved Wegovy in March 2024 to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and either obesity or overweight, on top of its weight-management approval. A drug with a cardiovascular indication is easier to get covered than one without, and coverage is what determines whether you are a cash payer at all.
Cash Price vs. Insurance
If you have commercial insurance that actually covers your drug, use it. Both cards bring you to as little as $25 a month. Neither card is available to you if you are uninsured, and both exclude government beneficiaries.
The caps matter more than the headline. Lilly’s Zepbound card terms state maximum savings of $100 per one-month fill, $300 per three-month fill, and $1,300 per calendar year across a maximum of 13 fills, and the card expires 12/31/2026. Novo Nordisk’s Wegovy offer is capped at $100 in savings per month. If your plan’s cost share is larger than the cap, you pay the difference, and the $25 headline does not apply.
Medicare is the sharpest divergence between these two drugs. Medicare.gov states that starting July 1, 2026 the temporary Medicare GLP-1 Bridge covers Foundayo, Wegovy in injection or tablet form, and Zepbound in KwikPen form only, with the program explicitly not covering single-dose Zepbound vials or pens. Eligible Part D beneficiaries pay $50 a month, and Medicare.gov notes you are not eligible if you already get GLP-1s through your Part D plan or if you have type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease.
For everyone else, self-pay is not a fallback. It is the price, and it is open regardless of insurance status. Self-pay purchases do not count toward a deductible or out-of-pocket maximum, which is the honest trade-off if you are on a high-deductible plan. Our fair price checker helps sanity-check the surrounding costs like the prescribing visit.
How to Pay Less
-
Buy manufacturer-direct on whichever drug you are prescribed. LillyDirect and NovoCare Pharmacy are the floor. The pharmacy’s own acquisition cost per CMS NADAC is higher than either self-pay price, so a walk-in counter cannot realistically beat them on brand.
-
Ask about the Wegovy tablet if you are on semaglutide. At $149 a month for 1.5 mg and $299 for 25 mg, tablets undercut every pen price on either brand. Our oral Wegovy guide covers the full tablet ladder. Whether a tablet suits you is a clinical decision.
-
Claim the $199 introductory fills before December 31, 2026. New self-pay Wegovy patients pay $199 for the first two monthly fills of the 0.25 mg and 0.5 mg doses. That is $300 you get once.
-
Protect the Zepbound refill window. Set a reminder 40 days out. On 10 mg and above it is a $250 monthly difference between $449 and $699. Our guide to the cheapest way to get Zepbound walks through the rest of the Zepbound levers, and the Zepbound savings card page covers who qualifies.
-
Do not expect a coupon card to beat either program. Discount cards do real work on generics and very little on brand GLP-1s. Our GoodRx vs. SingleCare comparison explains where cards win and where they do not.
-
Budget the prescribing visit separately. Both drugs need an active prescription and ongoing follow-up. A free or sliding-scale clinic can handle that cheaply if a cash office visit is out of reach.
Bottom Line
As of September 2026, a cash payer at a maintenance dose pays $449 a month for Zepbound and $349 for a Wegovy pen, which is $5,388 versus $4,188 across a year. Wegovy tablets are cheaper still at $299 a month for the top dose. Those are published manufacturer prices, not estimates.
The catch is that you rarely get to choose. These are different molecules with different approved uses, so the prescription you can be written decides which ladder you are on. What you do control is the channel, the format, and the refill calendar, and those three levers are worth thousands of dollars a year. If you are comparing tirzepatide brands rather than molecules, see our Zepbound vs. Mounjaro cost comparison and the molecule-level tirzepatide cost guide.